CRISPR Therapeutics CRSP Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$568.53M-47.4% | -$581.6M-58.8% | -$488.3M— | -$467.8M— | -$385.66M— | ||
| $19.06M-0.5% | $19.48M+1.1% | $18.66M-3.4% | $18.97M-2.8% | $19.16M-2.3% | ||
| $68.61M-21.5% | $72.5M-16.3% | $76.37M-8.0% | $81.31M-0.2% | $87.37M+9.8% | ||
| -$399.96M-30.5% | -$345.01M-142% | -$302.49M-60.2% | -$324.77M-167% | -$306.47M-92.2% | ||
| $1.21M-12.6% | $914K-51.9% | $651K-72.7% | $796K-81.4% | $1.39M-80.6% | ||
| —— | —— | —— | —— | —— | ||
| $1.01B+2,615% | $426.03M+28.1% | $326.49M-7.9% | $39.36M-88.6% | $37.1M-89.8% | ||
| $184.61M— | $49.3M— | —— | —— | —— | ||
| -$401.18M-30.3% | -$345.93M-139% | -$303.14M-58.5% | -$325.57M-158% | -$307.86M-84.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does CRISPR Therapeutics's cash flow data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.